May 8 (Reuters) - The European drugs regulator said on Thursday its safety committee has confirmed suicidal thoughts as a side effect of Organon's OGN.N anti hair-loss drug finasteride, following an EU-wide review of available data.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.